兔多克隆抗体to RhoGDI (phospho S174)
The antibody detects endogenous levels of RhoGDI only when phosphorylated at serine 174.
Synthesized phosphopeptide derived from human RhoGDI around the phosphorylation site of serine 174 (R-G-S
IHC-P: Human cervix carcinoma tissue.
WB: HUVEC cells treated with EGF.
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Preservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS (without Mg 2+ and Ca 2++), 150mM Sodium chloride, pH 7.4
Concentration information loading...
Immunogen affinity purified
The antibody was purified by affinity chromatography using epitope specific phosphopeptide. The antibody against non phosphopeptide was removed by chromatography using non phosphopeptide corresponding to the phosphorylation site.
Abpromise guarantee covers the use of
in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/500 - 1/1000. Predicted molecular weight: 23 kDa.
1/50 - 1/100.
Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them.
Belongs to the Rho GDI family.
Information by UniProt
GDIA 1 antibody
Western blot - RhoGDI (phospho S174) antibody (ab74142)
All lanes : Anti-RhoGDI (phospho S174) antibody (ab74142) at 1/500 dilution Lane 1 : HUVEC cells treated with EGF (200ng/ml, 30mins) Lane 2 : HUVEC cells treated with EGF (200ng/ml, 30mins) with phosphopeptide at 10 µg Lysates/proteins at 30 µg per lane. Predicted band size : 23 kDa Observed band size : 23 kDa Additional bands at : 105 kDa,60 kDa. We are unsure as to the identity of these extra bands.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - RhoGDI (phospho S174) antibody (ab74142)
Human cervix carcinoma tissue stained with ab74142 (1/50 dilution).
1: No phosphopeptide
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"